Literature DB >> 12727131

Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.

Fabrice Duval1, Marie-Claude Mokrani, José Monreal, Paul Bailey, Marcelo Valdebenito, Marc-Antoine Crocq, Jean-Paul Macher.   

Abstract

This study examined the prolactin (PRL), adrenocorticotropin (ACTH) and cortisol responses to the direct DA receptor agonist apomorphine (APO) and the selective 5HT-releasing agent d-fenfluramine (d-FEN) in 20 untreated inpatients with DSM-IV schizophrenia and without a history of suicide attempt, compared to 23 hospitalized healthy controls. We hypothesized that different patterns of responsiveness of the DA and 5-HT systems might be associated with specific schizophrenic symptom clusters. A positive correlation was observed between pituitary-adrenal response to APO and d-FEN tests (i.e. deltaACTH and deltacortisol) in the overall population and in schizophrenic patients. Pituitary-adrenal response to APO was lower in patients than in normal controls. Moreover, lower pituitary-adrenal response to APO and d-FEN was associated with increased severity of BPRS thought disturbance score. Lower pituitary-adrenal responses to APO (and to a lesser degree to d-FEN) differentiated paranoid from disorganized schizophrenic patients. Neither PRL suppression to APO, nor PRL stimulation to d-FEN were altered in schizophrenic patients. Our results suggest that decreased hypothalamic DA receptor activity (possibly secondary to increased presynaptic DA release) together with relatively decreased 5-HT tone characterize paranoid SCH, while normal hypothalamic DA receptor activity together with relatively increased 5-HT tone characterize the disorganized SCH subtype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727131     DOI: 10.1016/s0306-4530(02)00047-1

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

1.  Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Eduard Parellada; Miguel Bernardo; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2011-08-09       Impact factor: 4.939

2.  Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Alexis Erb; Vlad Danila; Felix Gonzalez Lopera; Ludovic Jeanjean
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

3.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

4.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

5.  A variant in the 3'-untranslated region of the MC2R gene decreases the risk of schizophrenia in a female Han Chinese population.

Authors:  Liang Tang; Qin Xiang; Ju Xiang; Jianming Li; Danna Chen
Journal:  J Int Med Res       Date:  2021-07       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.